Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hypoactive Sexual Desire Disorder

Hypoactive Sexual Desire Disorder

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hypoactive Sexual Desire Disorder

8 trials tracked for Hypoactive Sexual Desire Disorder: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 6499 citations.

8Trials tracked
5Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 2 Phase 3 3 Phase 2 2 Other / NA 1
  1. Phase 3 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder Completed · 6,499 cited
  2. Phase 3 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder Completed · 6,496 cited
  3. Phase 4 Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder Completed · 20 cited
  4. Phase 4 Testosterone Patch's Effects on the Cardiovascular System and Libido Completed
  5. Phase 3 Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women Completed
  6. Phase 2 Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder Completed
Show 2 more trials
  1. Phase 2 Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men Completed
  2. N/A A Mindfulness-based Intervention for Older Women With Low Sexual Desire Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Hypoactive Sexual Desire Disorder: what the trials found

Bremelanotide has demonstrated efficacy in improving several metrics of sexual function and desire. Clinical trials showed significant improvements in the number of satisfying sexual events (SSE) 7, as well as improvements in arousal domain scores and satisfaction with arousal 7.

Studies evaluating fixed doses of Bremelanotide reported measurable changes in mean Desire Score (Q3), Satisfaction with Desire Score (Q4), and total FSDS-DAO scores [3, 4]. Additionally, the Intrinsa Transdermal testosterone patch was associated with a libido score of 5.05 on the B-PFSF scale 2.

Safety data for a Testosterone Transdermal System in postmenopausal women with HSDD indicated zero instances of endometrial hyperplasia over one year, regardless of whether the patients were using concomitant estrogen and progestin therapy 5.

Recent results — preliminary, needs further review

  • Bupropion hydrochloride sustained-release showed more participants with improved scores on the CGI-SF at week 6 compared to placebo (21 vs 10), though specific p-values for this comparison were not provided 6.
  • A mindfulness-based multicomponent intervention was found feasible, with significantly higher enrollment in all sessions compared to a control group (22 vs 15; p=0.027) 8.

For the clinician treating this condition

  • Bremelanotide is associated with statistically significant improvements in satisfying sexual events and arousal scores 7.
  • Fixed-dose Bremelanotide has been shown to impact multiple dimensions of desire, including satisfaction and total FSDS-DAO scores [3, 4].
  • Transdermal testosterone systems show no evidence of endometrial hyperplasia in postmenopausal women with HSDD over a one-year period 5.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.